Biosimilar Renflexis Now Available

Renflexis is being commercialized by Merck and is available as 100mg single-dose vials for IV injection
Renflexis is being commercialized by Merck and is available as 100mg single-dose vials for IV injection

Samsung Bioepis announced the launch of Renflexis (infliximab-abda) for Injection, a biosimilar of Remicade (infliximab; Janssen).

Renflexis, a tumor necrosis factor (TNF) blocker, was approved by the Food and Drug Administration (FDA) in April 2017. It is indicated for the following conditions:

  • To reduce signs and symptoms and induce and maintain clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. To reduce the number of draining enterocutaneous and rectovaginal fistulas and maintain fistula closure in adult patients with fistulizing Crohn's disease.
  • To reduce signs and symptoms and induce and maintain clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.
  • To reduce signs and symptoms, induce and maintain clinical remission and mucosal healing, and eliminate corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
  • In combination with methotrexate, to reduce signs and symptoms, inhibit the progression of structural damage, and improve physical function in patients with moderately to severely active rheumatoid arthritis.
  • To reduce signs and symptoms in patients with active ankylosing spondylitis.
  • To reduce signs and symptoms of active arthritis, inhibit the progression of structural damage, and improve physical function in patients with psoriatic arthritis.
  • To treat adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. 

Related Articles

Infliximab products work by neutralizing the biological activity of TNF-alpha by binding with high affinity to the soluble and transmembrane forms of TNF-alpha and inhibiting the binding of TNF-alpha with its receptors. 

Renflexis is being commercialized by Merck and is available as 100mg single-dose vials for intravenous (IV) injection.

For more information call (877) 888-4231 or visit Renflexis.com.